Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
12
|
pubmed:dateCreated |
1998-9-17
|
pubmed:abstractText |
A prospective study of the pharmacokinetics of itraconazole solution was performed in 11 patients who underwent allogeneic BMT (day of BMT = day 0) after a conditioning regimen including total body irradiation (TBI). Itraconazole solution (400 mg once a day) was given 7 days before BMT and continued up to the end of neutropenia unless another antifungal treatment was necessary. Blood samples were collected before itraconazole intake (Cmin) and 4 h later (Cmax) every other day for assays of itraconazole (ITRA) and its active metabolite hydroxy-itraconazole (OH-ITRA). The mean values of Cmin ITRA and OH-ITRA, respectively, were 287 +/- 109 ng/ml and 629 +/- 227 ng/ml at day -1 and 378 +/- 147 ng/ml and 725 +/- 242 ng/ml at day +1. The maximum Cmin values were observed at day +3. Six patients at day -1 (54%) and 8 at day +1 (72%) had satisfactory residual plasma concentrations of at least 250 ng/ml of unchanged ITRA. From day +1 to day +9, eight patients discontinued the itraconazole treatment, five of them had satisfactory plasma residual concentrations at this time. This work shows a good bioavailability of itraconazole oral solution during the early phase after allogeneic BMT, but more data are needed for the late phases.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0268-3369
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
21
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1239-43
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:9674858-Administration, Oral,
pubmed-meshheading:9674858-Adult,
pubmed-meshheading:9674858-Antifungal Agents,
pubmed-meshheading:9674858-Bone Marrow Transplantation,
pubmed-meshheading:9674858-Female,
pubmed-meshheading:9674858-Humans,
pubmed-meshheading:9674858-Itraconazole,
pubmed-meshheading:9674858-Male,
pubmed-meshheading:9674858-Middle Aged,
pubmed-meshheading:9674858-Solutions,
pubmed-meshheading:9674858-Transplantation, Homologous,
pubmed-meshheading:9674858-Whole-Body Irradiation
|
pubmed:year |
1998
|
pubmed:articleTitle |
Pharmacokinetics of itraconazole oral solution in allogeneic bone marrow transplant patients receiving total body irradiation.
|
pubmed:affiliation |
Unité de Greffe de Moëlle Osseuse, Service d'Hematologie, Hôpital E Herriot, Lyon, France.
|
pubmed:publicationType |
Journal Article
|